Ocrevus is a medicine that represents a different scientific approach to treating multiple sclerosis. It targets a type of immune cell called the CD20-positive B cell that plays a key role in the disease.
OCREVUS has twice-yearly (six-monthly) dosing and is the first and only therapy approved for relapsing multiple sclerosis (RMS; including RRMS and active, or relapsing, secondary progressive MS [SPMS], in addition to clinically isolated syndrome [CIS] in the U.S.) and primary progressive MS (PPMS). OCREVUS is approved across North America, South America, the Middle East, Europe, as well as in Australia.
Ocrevus was designated as a Breakthrough Therapy by the U.S. Food and Drug Administration (FDA), and approved by the FDA in March 2017 and by the European Commission in January 2018.